The Prognostic Value of the DNMT3A Biomarker in Cytogenetically Normal Patients with Acute Myeloid Leukemia
Guideline Objective
To determine if testing for DNMT3A mutation in this patient population determines prognosis with standard indication and consolidation therapy, as a guide to choosing alternative treatment if appropriate.
Patient Population
AML patients with a normal cytogenetic profile.
Intended Guideline Users
Clinicians, patients and funding bodies.
Research Question(s)
What is the prognostic value of DNMT3A mutation screening in cytogenetically normal patients with acute myeloid leukemia (AML)?
Modality:
Pathology and Laboratory Testing
PEBC:
PEBC
Guideline Identifier:
MOAC 1
Cancer Continuum:
Treatment
Cancer Type:
Type of Content:
Authors:
B. Leber
N. Ismaila
S. Kamel-Reid
M. Rutherford
Molecular Oncology Advisory Committee
Universal Date:
2013-11-27 00:00:00